Novartis continues to grow with further core margin expansion and achieves important innovation milestonesGlobeNewsWire • 02/01/23
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5GlobeNewsWire • 12/13/22
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNHGlobeNewsWire • 12/08/22
Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancerGlobeNewsWire • 12/05/22
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASHGlobeNewsWire • 11/22/22